NO20032734D0 - Nye 1,2-difenylazetidinonderivater, fremgangsmåte for deres fremstilling, legemidler som inneholder nevnte forbindelser og anvendelse avdisse for behandling av sykdommer fra lipidstoffskiftet - Google Patents

Nye 1,2-difenylazetidinonderivater, fremgangsmåte for deres fremstilling, legemidler som inneholder nevnte forbindelser og anvendelse avdisse for behandling av sykdommer fra lipidstoffskiftet

Info

Publication number
NO20032734D0
NO20032734D0 NO20032734A NO20032734A NO20032734D0 NO 20032734 D0 NO20032734 D0 NO 20032734D0 NO 20032734 A NO20032734 A NO 20032734A NO 20032734 A NO20032734 A NO 20032734A NO 20032734 D0 NO20032734 D0 NO 20032734D0
Authority
NO
Norway
Prior art keywords
diphenyllazetidinone
diseases
derivatives
compounds
preparation
Prior art date
Application number
NO20032734A
Other languages
English (en)
Other versions
NO20032734L (no
NO325496B1 (no
Inventor
Heiner Glombik
Werner Kramer
Stefanie Flohr
Wendelin Frick
Hubert Heuer
Gerhard Jaehne
Andreas Lindenschmidt
Hans-Ludwig Schaefer
Original Assignee
Aventis Pharma Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26008042&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NO20032734(D0) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from DE10064398A external-priority patent/DE10064398A1/de
Priority claimed from DE2001152981 external-priority patent/DE10152981A1/de
Application filed by Aventis Pharma Gmbh filed Critical Aventis Pharma Gmbh
Publication of NO20032734D0 publication Critical patent/NO20032734D0/no
Publication of NO20032734L publication Critical patent/NO20032734L/no
Publication of NO325496B1 publication Critical patent/NO325496B1/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D205/00—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom
    • C07D205/02—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings
    • C07D205/06—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • C07D205/08—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with one oxygen atom directly attached in position 2, e.g. beta-lactams
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/397—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having four-membered rings, e.g. azetidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/06—Free radical scavengers or antioxidants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F7/00—Compounds containing elements of Groups 4 or 14 of the Periodic Table
    • C07F7/02—Silicon compounds
    • C07F7/08—Compounds having one or more C—Si linkages
    • C07F7/18—Compounds having one or more C—Si linkages as well as one or more C—O—Si linkages
    • C07F7/1804—Compounds having Si-O-C linkages

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Vascular Medicine (AREA)
  • Endocrinology (AREA)
  • Cardiology (AREA)
  • Urology & Nephrology (AREA)
  • Toxicology (AREA)
  • Emergency Medicine (AREA)
  • Biochemistry (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Saccharide Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
NO20032734A 2000-12-21 2003-06-16 Nye difenylazetidinoner, fremgangsmate for deres fremstilling, legemidler som inneholder disse forbindelsene og anvendelse av disse i terapeutisk behandling NO325496B1 (no)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DE10064398A DE10064398A1 (de) 2000-12-21 2000-12-21 Neue Diphenylazetidinone, Verfahren zu deren Herstellung, diese Verbindungen enthaltende Arzneimittel und deren Verwendung
DE2001152981 DE10152981A1 (de) 2001-10-26 2001-10-26 Neue Diphenylazetidinone, Verfahren zu deren Herstellung, diese Verbindungen enthaltende Arzneimittel und deren Verwendung
PCT/EP2001/014531 WO2002050027A1 (de) 2000-12-21 2001-12-11 Neue diphenzylazetidinone, verfahren zu deren herstellung, diese verbindungen enthaltende arzneimittel und deren verwendung zur behandlung von lipidstoffwechselstörungen

Publications (3)

Publication Number Publication Date
NO20032734D0 true NO20032734D0 (no) 2003-06-16
NO20032734L NO20032734L (no) 2003-08-18
NO325496B1 NO325496B1 (no) 2008-05-19

Family

ID=26008042

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20032734A NO325496B1 (no) 2000-12-21 2003-06-16 Nye difenylazetidinoner, fremgangsmate for deres fremstilling, legemidler som inneholder disse forbindelsene og anvendelse av disse i terapeutisk behandling

Country Status (28)

Country Link
US (5) US6992067B2 (no)
EP (1) EP1345895B1 (no)
JP (1) JP4605990B2 (no)
KR (1) KR100833089B1 (no)
CN (1) CN1217927C (no)
AR (1) AR034010A1 (no)
AT (1) ATE349425T1 (no)
AU (2) AU1609702A (no)
BR (1) BR0116325A (no)
CA (1) CA2431983C (no)
CY (1) CY1106383T1 (no)
CZ (1) CZ20031732A3 (no)
DE (1) DE50111751D1 (no)
DK (1) DK1345895T3 (no)
EE (1) EE200300236A (no)
ES (1) ES2277890T3 (no)
HR (1) HRP20030498A2 (no)
HU (1) HUP0401081A3 (no)
IL (2) IL156550A0 (no)
MX (1) MXPA03005155A (no)
NO (1) NO325496B1 (no)
NZ (1) NZ526593A (no)
PL (1) PL362379A1 (no)
PT (1) PT1345895E (no)
RS (1) RS50864B (no)
SK (1) SK7822003A3 (no)
TW (1) TWI293626B (no)
WO (1) WO2002050027A1 (no)

Families Citing this family (108)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6584357B1 (en) * 2000-10-17 2003-06-24 Sony Corporation Method and system for forming an acoustic signal from neural timing difference data
US6982251B2 (en) 2000-12-20 2006-01-03 Schering Corporation Substituted 2-azetidinones useful as hypocholesterolemic agents
HUP0401081A3 (en) * 2000-12-21 2010-06-28 Sanofi Aventis Deutschland Novel 1,2-diphenzylazetidinones, method for producing the same, medicaments containing said compounds, and their use
RS20100015A (sr) 2001-01-26 2010-12-31 Schering Corporation Kombinacija aktivatora receptora aktiviranog peroksizom- proliferatorom (ppar) fenofibrata sa inhibitorom apsorpcije sterola ezetimibom za vaskularne indikacije
EP1353695A2 (en) * 2001-01-26 2003-10-22 Schering Corporation Combinations of nicotinic acid and derivatives thereof and sterol absorption inhibitor(s) and treatments for vascular indications
US7071181B2 (en) 2001-01-26 2006-07-04 Schering Corporation Methods and therapeutic combinations for the treatment of diabetes using sterol absorption inhibitors
ATE369851T1 (de) * 2001-01-26 2007-09-15 Schering Corp Kombinationen von gallensäuresequestriermitteln und hemmern der sterolabsorption zur behandlung von kardiovaskulären indikationen
IL156488A0 (en) * 2001-01-26 2004-01-04 Schering Corp Combinations of sterol absorption inhibitor(s) with blood modifier(s) for treating vascular conditions
PT1355644E (pt) 2001-01-26 2006-11-30 Schering Corp Utilização de compostos azetidinona substituídos para o tratamento de sitosterolemia
IL156585A0 (en) * 2001-01-26 2004-01-04 Schering Corp Combinations of sterol absorption inhibitor(s) with cardiovascular agent(s) for the treatment of vascular conditions
IL157552A0 (en) 2001-03-28 2004-03-28 Schering Corp Enantioselective synthesis of azetidinone intermediate compounds
EP1429756B1 (en) 2001-09-21 2006-11-22 Schering Corporation Treatment of xanthoma with azetidinone derivatives as sterol absorption inhibitors
US7056906B2 (en) 2001-09-21 2006-06-06 Schering Corporation Combinations of hormone replacement therapy composition(s) and sterol absorption inhibitor(s) and treatments for vascular conditions in post-menopausal women
US7053080B2 (en) 2001-09-21 2006-05-30 Schering Corporation Methods and therapeutic combinations for the treatment of obesity using sterol absorption inhibitors
US20030119808A1 (en) * 2001-09-21 2003-06-26 Schering Corporation Methods of treating or preventing cardiovascular conditions while preventing or minimizing muscular degeneration side effects
US20030204096A1 (en) * 2002-03-25 2003-10-30 Schering Corporation Enantioselective synthesis of azetidinone intermediate compounds
US7176194B2 (en) 2002-06-19 2007-02-13 Sanofi-Aventis Deutschland Gmbh Ring-substituted diphenylazetidinones, process for their preparation, medicaments comprising these compounds, and their use
US7671047B2 (en) 2002-06-19 2010-03-02 Sanofi-Aventis Deutschland Gmbh Cationically substituted diphenylazetidinones, process for their preparation, medicaments comprising these compounds, and their use
DE10227507A1 (de) * 2002-06-19 2004-01-08 Aventis Pharma Deutschland Gmbh Kationisch substituierte Diphenylazetidinone, Verfahren zu deren Herstellung, diese Verbindungen enthaltende Arzneimittel und deren Verwendung
DE10227508A1 (de) * 2002-06-19 2004-01-08 Aventis Pharma Deutschland Gmbh Säuregruppen-substituierte Diphenylazetidinone, Verfahren zu deren Herstellung, diese Verbindungen enthaltende Arzneimittel und deren Verwendung
US7176193B2 (en) 2002-06-19 2007-02-13 Sanofi-Aventis Deutschland Gmbh Acid-group-substituted diphenylazetidinones, process for their preparation, medicaments comprising these compounds, and their use
GB0215579D0 (en) * 2002-07-05 2002-08-14 Astrazeneca Ab Chemical compounds
JP2006508188A (ja) 2002-11-06 2006-03-09 シェーリング　コーポレイション 脱髄の処置のためのコレステロール吸収インヒビター
DE10308355A1 (de) 2003-02-27 2004-12-23 Aventis Pharma Deutschland Gmbh Aryl-cycloalkyl substituierte Alkansäurederivate, Verfahren zu ihrer Herstellung und ihre Anwendung als Arzneimittel
US7148246B2 (en) 2003-02-27 2006-12-12 Sanofi-Aventis Deutschland Gmbh Cycloalkyl derivatives having bioisosteric carboxylic acid groups, processes for their preparation and their use as pharmaceuticals
DE10308352A1 (de) 2003-02-27 2004-09-09 Aventis Pharma Deutschland Gmbh Arylcycloalkylderivate mit verzweigten Seitenketten, Verfahren zu ihrer Herstellung und ihre Anwendung als Arzneimittel
DE10308351A1 (de) 2003-02-27 2004-11-25 Aventis Pharma Deutschland Gmbh 1,3-substituierte Cycloalkylderivate mit sauren, meist heterocyclischen Gruppen, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
DE10308353A1 (de) 2003-02-27 2004-12-02 Aventis Pharma Deutschland Gmbh Diarylcycloalkylderivate, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
CN1756756A (zh) 2003-03-07 2006-04-05 先灵公司 取代的2－吖丁啶酮化合物、其制剂及其治疗高胆甾醇血症的用途
CN1756755A (zh) 2003-03-07 2006-04-05 先灵公司 取代的2－吖丁啶酮化合物、其制剂及其治疗高胆甾醇血症的用途
DE602004016123D1 (de) 2003-03-07 2008-10-09 Schering Corp Substituierte azetidinon-derivate, deren pharmazeutische formulierungen und deren verwendung zur behandlung von hypercholesterolemia
US7459442B2 (en) 2003-03-07 2008-12-02 Schering Corporation Substituted azetidinone compounds, processes for preparing the same, formulations and uses thereof
DE10314610A1 (de) * 2003-04-01 2004-11-04 Aventis Pharma Deutschland Gmbh Neues Diphenylazetidinon mit verbesserten physiologischen Eigenschaften, Verfahren zu dessen Herstellung, diese Verbindungen enthaltende Arzneimittel und dessen Verwendung
US20070135357A1 (en) * 2003-10-30 2007-06-14 Sings Heather L Anti-hypercholesterolemic compounds
EP1918000A2 (en) 2003-11-05 2008-05-07 Schering Corporation Combinations of lipid modulating agents and substituted azetidinones and treatments for vascular conditions
DE602004008100T2 (de) * 2003-11-10 2008-04-30 Microbia Inc., Cambridge 4-biarylyl-1-phenylazetidin-2-one
SI1682499T1 (sl) * 2003-11-10 2008-02-29 Microbia Inc 4-biarilil-1-fenilazetidin-2-oni
EP1689383B1 (en) 2003-11-19 2012-10-31 Metabasis Therapeutics, Inc. Novel phosphorus-containing thyromimetics
WO2005062824A2 (en) 2003-12-23 2005-07-14 Merck & Co., Inc. Anti-hypercholesterolemic compounds
CA2550215A1 (en) 2003-12-23 2005-07-07 Astrazeneca Ab Diphenylazetidinone derivates possessing cholesterol absorption inhibitory activity
US7241787B2 (en) 2004-01-25 2007-07-10 Sanofi-Aventis Deutschland Gmbh Substituted N-cycloexylimidazolinones, process for their preparation and their use as medicaments
EP1586573B1 (en) 2004-04-01 2007-02-07 Sanofi-Aventis Deutschland GmbH Oxadiazolones, processes for their preparation and their use as pharmaceuticals
CA2567149A1 (en) 2004-05-21 2005-12-01 Sanofi-Aventis Deutschland Gmbh Method for producing 1,4-diphenyl azetidinone derivatives
DOP2005000123A (es) * 2004-07-02 2011-07-15 Merck Sharp & Dohme Inhibidores de cetp
JP2008514718A (ja) * 2004-09-29 2008-05-08 シェーリング コーポレイション 置換アゼチドノンおよびｃｂ１アンタゴニストの組み合わせ
WO2006060461A1 (en) 2004-12-03 2006-06-08 Schering Corporation Substituted piperazines as cb1 antagonists
CN101119966B (zh) 2004-12-20 2014-08-13 默沙东公司 合成2-吖丁啶酮的方法
TW200726746A (en) 2005-05-06 2007-07-16 Microbia Inc Processes for production of 4-biphenylylazetidin-2-ones
JP2008540557A (ja) * 2005-05-11 2008-11-20 マイクロビア インコーポレーテッド フェノール型４−ビフェニリルアゼチジン−２−オンの製造方法
US7737155B2 (en) 2005-05-17 2010-06-15 Schering Corporation Nitrogen-containing heterocyclic compounds and methods of use thereof
AU2006249905A1 (en) * 2005-05-25 2006-11-30 Microbia, Inc. Processes for production of 4-(biphenylyl)azetidin-2-one phosphonic acids
DE102005026762A1 (de) 2005-06-09 2006-12-21 Sanofi-Aventis Deutschland Gmbh Azolopyridin-2-on-derivate als Inhibitoren von Lipasen und Phospholipasen
US7696177B2 (en) * 2005-06-15 2010-04-13 Merck Sharp & Dohme Corp. Anti-hypercholesterolemic compounds
JP2008546784A (ja) * 2005-06-20 2008-12-25 シェーリング コーポレイション ヒスタミンｈ３アンタゴニストとして有用なピペリジン誘導体
SA06270191B1 (ar) 2005-06-22 2010-03-29 استرازينيكا ايه بي مشتقات من 2- أزيتيدينون جديدة باعتبارها مثبطات لامتصاص الكوليسترول لعلاج حالات فرط نسبة الدهون في الدم
TW200806623A (en) * 2005-10-05 2008-02-01 Merck & Co Inc Anti-hypercholesterolemic compounds
CA2634940A1 (en) * 2005-12-21 2007-07-05 Schering Corporation Treatment of nonalcoholic fatty liver disease using cholesterol lowering agents and h3 receptor antagonist/inverse agonist
BRPI0706623A2 (pt) * 2006-01-18 2011-04-12 Schering Corp moduladores de receptor canabinóide
AR060623A1 (es) 2006-04-27 2008-07-02 Astrazeneca Ab Compuestos derivados de 2-azetidinona y un metodo de preparacion
BRPI0715160A2 (pt) 2006-08-08 2013-06-11 Sanofi Aventis imidazolidina-2,4-dionas substituÍdas por arilamimoaril-alquil-, processo para preparÁ-las, medicamentos compeendendo estes compostos, e seu uso
US20080103122A1 (en) * 2006-09-05 2008-05-01 Schering Corporation Pharmaceutical combinations for lipid management and in the treatment of atherosclerosis and hepatic steatosis
US20080070890A1 (en) * 2006-09-15 2008-03-20 Burnett Duane A Spirocyclic Azetidinone Compounds and Methods of Use Thereof
CA2663500A1 (en) * 2006-09-15 2008-03-20 Schering Corporation Spiro-condensed azetidine derivatives useful in treating pain, diabetes and disorders of lipid metabolism
CN101541805A (zh) 2006-09-15 2009-09-23 先灵公司 用于治疗疼痛和脂代射紊乱的氮杂环丁烷和氮杂环丁酮衍生物
MX2009002921A (es) * 2006-09-15 2009-04-01 Schering Corp Derivados de azetidinona para el tratamiento de trastornos del metabolismo lipidico.
AU2007318058A1 (en) * 2006-11-02 2008-05-15 Merck Sharp & Dohme Corp. Heterocyclyl-substituted anti-hypercholesterolemic compounds
US20100197564A1 (en) * 2007-04-19 2010-08-05 Schering Corporation Diaryl morpholines as cb1 modulators
US20080319221A1 (en) * 2007-06-22 2008-12-25 Bernd Junker Esters of Pentahydroxyhexylcarbamoyl Alkanoic Acids
DE102007029612A1 (de) 2007-06-27 2009-01-08 Sanofi-Aventis Deutschland Gmbh Verfahren zur Herstellung von Pentahydroxyhexylcarbamoylundekan- säurebenzylester
US20080319218A1 (en) * 2007-06-22 2008-12-25 Andreas Haubrich Processes for Making and Using Benzyl Pentahydroxyhexylcarbamoylundecanoate
EP2548874A3 (en) * 2007-06-28 2013-05-15 Intervet International B.V. Substituted piperazines as CB1 antagonists
US20100286160A1 (en) * 2007-06-28 2010-11-11 Intervet Inc. Substituted piperazines as cb1 antagonists
EP2025674A1 (de) 2007-08-15 2009-02-18 sanofi-aventis Substituierte Tetrahydronaphthaline, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
DE102007054497B3 (de) 2007-11-13 2009-07-23 Sanofi-Aventis Deutschland Gmbh Neue kristalline Diphenylazetidinonhydrate und Verfahren zu deren Herstellung
WO2009097995A1 (de) * 2008-02-07 2009-08-13 Sanofi-Aventis Neue phenyl-substituierte imidazolidine, verfahren zu deren herstellung, diese verbindungen enthaltende arzneimittel und deren verwendung
SG171985A1 (en) 2008-12-11 2011-07-28 Agency For Science Techonology And Res Glucose-peg conjugates for reducing glucose transport into a cell
US20110243940A1 (en) 2008-12-16 2011-10-06 Schering Corporation Bicyclic pyranone derivatives and methods of use thereof
US20110245209A1 (en) 2008-12-16 2011-10-06 Schering Corporation Pyridopyrimidine derivatives and methods of use thereof
US20120046364A1 (en) 2009-02-10 2012-02-23 Metabasis Therapeutics, Inc. Novel Sulfonic Acid-Containing Thyromimetics, and Methods for Their Use
WO2010100255A1 (en) 2009-03-06 2010-09-10 Lipideon Biotechnology Ag Pharmaceutical hypocholesterolemic compositions
EP2414529A2 (en) 2009-04-01 2012-02-08 Matrix Laboratories Ltd Enzymatic process for the preparation of (s)-5-(4-fluoro-phenyl)-5-hydroxy- 1morpholin-4-yl-pentan-1-one, an intermediate of ezetimibe and further conversion to ezetimibe
CN101993403B (zh) * 2009-08-11 2012-07-11 浙江海正药业股份有限公司 氮杂环丁酮类化合物及医药应用
DE102010015123A1 (de) 2010-04-16 2011-10-20 Sanofi-Aventis Deutschland Gmbh Benzylamidische Diphenylazetidinone, diese Verbindungen enthaltende Arzneimittel und deren Verwendung
EP2566497B1 (en) 2010-05-04 2015-07-29 Codexis, Inc. Biocatalysts for ezetimibe synthesis
EP3593802A3 (en) 2010-05-26 2020-03-25 Satiogen Pharmaceuticals, Inc. Bile acid recycling inhibitors and satiogens for treatment of diabetes, obesity, and inflammatory gastrointestinal conditions
US8933024B2 (en) 2010-06-18 2015-01-13 Sanofi Azolopyridin-3-one derivatives as inhibitors of lipases and phospholipases
ES2372460B1 (es) * 2010-07-09 2012-11-16 Moehs Ibérica S.L. Nuevo método para la preparación de ezetimiba.
WO2012120050A1 (de) 2011-03-08 2012-09-13 Sanofi Neue substituierte phenyl-oxathiazinderivate, verfahren zu deren herstellung, diese verbindungen enthaltende arzneimittel und deren verwendung
US8710050B2 (en) 2011-03-08 2014-04-29 Sanofi Di and tri- substituted oxathiazine derivatives, method for the production, method for the production thereof, use thereof as medicine and drug containing said derivatives and use thereof
WO2012120058A1 (de) 2011-03-08 2012-09-13 Sanofi Mit benzyl- oder heteromethylengruppen substituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung
WO2012120054A1 (de) 2011-03-08 2012-09-13 Sanofi Di- und trisubstituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung
EP2683704B1 (de) 2011-03-08 2014-12-17 Sanofi Verzweigte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung
EP2766349B1 (de) 2011-03-08 2016-06-01 Sanofi Mit carbozyklen oder heterozyklen substituierte oxathiazinderivate, verfahren zu deren herstellung, diese verbindungen enthaltende arzneimittel und deren verwendung
WO2012120056A1 (de) 2011-03-08 2012-09-13 Sanofi Tetrasubstituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung
EP2683703B1 (de) 2011-03-08 2015-05-27 Sanofi Neue substituierte phenyl-oxathiazinderivate, verfahren zu deren herstellung, diese verbindungen enthaltende arzneimittel und deren verwendung
US8809325B2 (en) 2011-03-08 2014-08-19 Sanofi Benzyl-oxathiazine derivatives substituted with adamantane and noradamantane, medicaments containing said compounds and use thereof
CN102219803B (zh) * 2011-04-20 2013-07-31 浙江大学 一种伊替米贝中间体的制备方法
EP2567959B1 (en) 2011-09-12 2014-04-16 Sanofi 6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
BR112014010223B8 (pt) 2011-10-28 2021-02-23 Lumena Pharmaceuticals Llc uso de uma composição compreendendo inibidores de reciclagem de ácido de bílis e forma de dosagem pediátrica
KR102051031B1 (ko) 2011-10-28 2019-12-02 루메나 파마수티컬즈, 인코포레이티드 고담혈증 및 담즙 정체성 간 질환 치료용 담즙산 재순환 억제제
CN102746249B (zh) * 2012-07-07 2013-12-25 山东诚创医药技术开发有限公司 一种依折麦布中间体的纯化精制方法
EP2968230A2 (en) 2013-03-15 2016-01-20 Lumena Pharmaceuticals, Inc. Bile acid recycling inhibitors for treatment of primary sclerosing cholangitis and inflammatory bowel disease
KR20160003664A (ko) 2013-03-15 2016-01-11 루메나 파마수티컬즈, 인코포레이티드 바렛 식도 및 위식도 역류 질환 치료용 담즙산 재순환 억제제
CN104513187B (zh) * 2015-01-09 2017-05-31 安润医药科技（苏州）有限公司 依折麦布及其中间体的合成方法
CA3129826A1 (en) 2019-02-12 2020-08-20 Mirum Pharmaceuticals, Inc. Methods for treating cholestasis
WO2020191163A1 (en) 2019-03-20 2020-09-24 Regeneron Pharmaceuticals, Inc. Treatment of increased lipid levels with sterol regulatory element binding protein cleavage-activating protein (scap) inhibitors
JP7574206B2 (ja) 2019-03-20 2024-10-28 リジェネロン・ファーマシューティカルズ・インコーポレイテッド ステロール調節エレメント結合転写因子１（ｓｒｅｂｆ１）阻害剤による上昇した脂質レベルの治療
WO2025049558A1 (en) 2023-08-29 2025-03-06 Regeneron Pharmaceuticals, Inc. Treatment of liver disease or metabolic disorder with folliculin interacting protein 1 (fnip1) inhibitors and/or folliculin (flcn) inhibitors

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5631365A (en) * 1993-09-21 1997-05-20 Schering Corporation Hydroxy-substituted azetidinone compounds useful as hypocholesterolemic agents
US5656624A (en) * 1994-12-21 1997-08-12 Schering Corporation 4-[(heterocycloalkyl or heteroaromatic)-substituted phenyl]-2-azetidinones useful as hypolipidemic agents
DE69621952T2 (de) * 1995-10-31 2003-01-16 Schering Corp., Kenilworth Zuckersubstituierte 2-azetidinone, verwendbar als hypocholesterdenische arzneimittel
CZ220498A3 (cs) 1996-01-17 1998-11-11 Novo Nordisk A/S Deriváty 1,2,4-thiadiazinu a 1,4-thiazinu, příprava a použití
US6225310B1 (en) 1996-01-17 2001-05-01 Novo Nordisk A/S Fused 1,2,4-thiadiazine derivatives, their preparation and use
NZ331813A (en) * 1996-03-11 2001-03-30 G Benzothiepine compounds having activity as inhibitors of ileal bile acid transport and taurocholate uptake
US5739321A (en) * 1996-05-31 1998-04-14 Schering Corporation 3-hydroxy γ-lactone based enantionselective synthesis of azetidinones
US6268343B1 (en) 1996-08-30 2001-07-31 Novo Nordisk A/S Derivatives of GLP-1 analogs
JP3149958B2 (ja) 1996-08-30 2001-03-26 ノボ ノルディスク アクティーゼルスカブ Ｇｌｐ―１誘導体
US5756470A (en) * 1996-10-29 1998-05-26 Schering Corporation Sugar-substituted 2-azetidinones useful as hypocholesterolemic agents
DE69723869T2 (de) 1996-12-31 2004-04-22 Dr. Reddy's Laboratories Ltd. Heterozyklische verbindungen, verfahren zu ihrer herstellung, pharmazeutische zusammensetzungen die diese enthalten und ihre anwendung in der behandlung von diabetis und verwandten krankheiten
EP1000066A1 (en) 1997-07-16 2000-05-17 Novo Nordisk A/S Fused 1,2,4-thiadiazine derivatives, their preparation and use
DE19825804C2 (de) * 1998-06-10 2000-08-24 Aventis Pharma Gmbh 1,4-Benzothiepin-1,1-dioxidderivate, Verfahren zu deren Herstellung und diese Verbindungen enthaltende Arzneimittel
DE19845405C2 (de) * 1998-10-02 2000-07-13 Aventis Pharma Gmbh Arylsubstituierte Propanolaminderivate und deren Verwendung
DE19916108C1 (de) * 1999-04-09 2001-01-11 Aventis Pharma Gmbh Mit Zuckerresten substituierte 1,4-Benzothiazepin-1,1-dioxidderivate, Verfahren zu deren Herstellung und deren Verwendung
AR023463A1 (es) * 1999-04-16 2002-09-04 Schering Corp Uso de compuestos de azetidinona
JP2004513076A (ja) 2000-07-25 2004-04-30 メルク　エンド　カムパニー　インコーポレーテッド 糖尿病治療で有用なｎ−置換インドール類
IL156552A0 (en) * 2000-12-21 2004-01-04 Aventis Pharma Gmbh Diphenyl azetidinone derivatives, method for the production thereof, medicaments containing these compounds, and their use
HUP0401081A3 (en) * 2000-12-21 2010-06-28 Sanofi Aventis Deutschland Novel 1,2-diphenzylazetidinones, method for producing the same, medicaments containing said compounds, and their use
US7176193B2 (en) * 2002-06-19 2007-02-13 Sanofi-Aventis Deutschland Gmbh Acid-group-substituted diphenylazetidinones, process for their preparation, medicaments comprising these compounds, and their use
US7671047B2 (en) * 2002-06-19 2010-03-02 Sanofi-Aventis Deutschland Gmbh Cationically substituted diphenylazetidinones, process for their preparation, medicaments comprising these compounds, and their use
US7176194B2 (en) * 2002-06-19 2007-02-13 Sanofi-Aventis Deutschland Gmbh Ring-substituted diphenylazetidinones, process for their preparation, medicaments comprising these compounds, and their use
DE10314610A1 (de) * 2003-04-01 2004-11-04 Aventis Pharma Deutschland Gmbh Neues Diphenylazetidinon mit verbesserten physiologischen Eigenschaften, Verfahren zu dessen Herstellung, diese Verbindungen enthaltende Arzneimittel und dessen Verwendung
DE102004025072A1 (de) * 2004-05-21 2005-12-15 Sanofi-Aventis Deutschland Gmbh Verfahren zur Herstellung von Diphenyl-azetidinon-Derivaten
DE102005055726A1 (de) * 2005-11-23 2007-08-30 Sanofi-Aventis Deutschland Gmbh Hydroxy-substituierte Diphenylazetidinone, Verfahren zu deren Herstellung, diese Verbindungen enthaltende Arzneimittel und deren Verwendung

Also Published As

Publication number Publication date
CA2431983A1 (en) 2002-06-27
JP4605990B2 (ja) 2011-01-05
CA2431983C (en) 2010-06-08
KR100833089B1 (ko) 2008-05-29
AU1609702A (en) 2002-07-01
DK1345895T3 (da) 2007-05-07
NO20032734L (no) 2003-08-18
PL362379A1 (en) 2004-10-18
IL156550A0 (en) 2004-01-04
US7576200B2 (en) 2009-08-18
NO325496B1 (no) 2008-05-19
CN1483021A (zh) 2004-03-17
EE200300236A (et) 2003-08-15
US7674773B2 (en) 2010-03-09
YU45403A (sh) 2006-05-25
JP2004516280A (ja) 2004-06-03
HUP0401081A3 (en) 2010-06-28
US20070208179A1 (en) 2007-09-06
US6992067B2 (en) 2006-01-31
DE50111751D1 (de) 2007-02-08
AU2002216097B2 (en) 2006-09-07
NZ526593A (en) 2005-02-25
RS50864B (sr) 2010-08-31
SK7822003A3 (en) 2003-12-02
US20080281092A1 (en) 2008-11-13
HK1060120A1 (en) 2004-07-30
US20020137689A1 (en) 2002-09-26
MXPA03005155A (es) 2003-09-10
AR034010A1 (es) 2004-01-21
CY1106383T1 (el) 2011-10-12
EP1345895B1 (de) 2006-12-27
ES2277890T3 (es) 2007-08-01
IL156550A (en) 2009-08-03
US20100160282A1 (en) 2010-06-24
TWI293626B (en) 2008-02-21
US20050267038A1 (en) 2005-12-01
WO2002050027A1 (de) 2002-06-27
BR0116325A (pt) 2003-10-14
ATE349425T1 (de) 2007-01-15
PT1345895E (pt) 2007-02-28
KR20030061460A (ko) 2003-07-18
CZ20031732A3 (cs) 2003-09-17
HRP20030498A2 (en) 2005-04-30
EP1345895A1 (de) 2003-09-24
US7488829B2 (en) 2009-02-10
CN1217927C (zh) 2005-09-07
HUP0401081A2 (hu) 2004-09-28

Similar Documents

Publication Publication Date Title
NO20032734L (no) Nye 1,2-difenylazetidinoner, fremgangsmåte for deres fremstilling, legemidler som inneholder disse forbindelsene og anvendelse av disse forbehandling av sykdommer fra lipidstoffskiftet
NO324227B1 (no) Cyclopropyl-kondenserte pyrrolidin-baserte forbindelser, farmasoytiske blandinger og kombinasjoner inneholdende slike samt anvendelse av slike for fremstilling av medikamenter for behandling av sykdommer
NO324251B1 (no) <Beta>-karbolinderivater, farmasoytisk preparat inneholdende samme, fremgangsmate for fremstilling av farmasoytisk preparat ved anvendelse av beta-karbolinderivater for fremstilling av medikament
EE200100495A (et) Sahhariidijääkidega asendatud 1,4-bensotiasepiin-1,1-dioksiidi derivaadid, meetod nende valmistamiseks, ühendite kasutamine ning neid sisaldav ravim
DE602004029580D1 (de) Substituierte indolderivate für eine pharmazeutische zusammensetzung zur behandlung von atemwegserkrankungen
IL163831A0 (en) Derivatives of aminoindazoles, method of preparation and intermediates of the method as drugs pharmaceutical compounds containing
NO20031694D0 (no) Krystallinsk monohydrat, fremgangsmåte for fremstilling derav og anvendelsederav til fremstilling av et medikament
NO20033594L (no) Fenetanolamin-derivater for behandling av luftveissykdommer
IL219397A0 (en) Compounds for the treatment of metabolic disorders, methods of preparing same, and pharmaceutical compositions containing same
NO20032733L (no) Difenylazetidinonderivater, fremgangsmåte for deres fremstilling, legemidler som inneholder disse forbindelsene og deres anvendelse
NO20034612L (no) 3,4-di-substituerte syklobuten-1,2-dioner, farmasoytiske preparater som omfatter forbindelsene, samt anvendelse av forbindelsene for tilvirkning av medikamenter for behandling av kjemokinformidlede sykdommer
NO20041277L (no) Farmasoytiske preparater for behandling av astma.
EE200200409A (et) 1,3-dihüdro-2H-indool-2-ooni derivaadid, nende valmistamismeetod ja neid sisaldavad farmatseutilised kompositsioonid
NO954942L (no) Nye erytromycinderivater, fremgangsmåte for deres fremstilling og anvendelse av derivatene som legemidler
NO20040268L (no) Nye 2H-pyridazin-3-derivater, farmasoytiske preparater inneholdende slike og fremgangsmate for fremstilling av den aktive ingrediensen
EE200300167A (et) Amidoalküülpiperidiini ja -piperasiini derivaadid, neid sisaldav farmatseutiline kompositsioon ningühendite kasutamine närvisüsteemi häirete raviks
NO20035438L (no) Farmasoytisk formulering for effektiv administrering av apomorfin, 6aR-(-)-N-propyl-norapomorfin og deres derivater og prodrugs derav
HUP0401747A3 (en) Piridazine derivatives of hydrazono-malonitriles, their use, process for preparation of the compounds and pharmaceutical compositions containing the compounds
DE60301570D1 (de) 1,2,3-substituierte indolizinderivate, fgf inhibitoren, verfahren zu ihrer herstellung und diese enthaltende pharmazeutische zubereitungen
NO20025394D0 (no) Formuleringer inneholdende et glukokorticoid legemiddel for behandling av bronkopulmonire sykdommer
NO326689B1 (no) Pyrrolidinderivater, anvendelse derav, farmasøytisk preparat samt fremgangsmåte for fremstilling av forbindelsene
FI20000780L (fi) Peroraalinen lääkemuoto lääkeaineen hallituksi vapauttamiseksi
NO20035586D0 (no) Fremgangsmåte for fremstilling av cykloheksanol-derivater
NO20034985L (no) Nye 5-tio-SS-D-xylopyranosid-derivater, fremgangsmåte for fremstilling derav, farmasöytiske blandinger inneholdende dem og den terapeutiskeanvendelse derav
NO20035642L (no) Fremgangsmate for fremstilling av derivater av 1,5-diaryl-3-trifluormetyl-delta2-pyrazoliner som er racemisk og enantiomerisk rene

Legal Events

Date Code Title Description
MM1K Lapsed by not paying the annual fees